Alejandro Balsa Criado-rekin lankidetzan egindako argitalpenak (19)

2023

  1. Recommendations by the Spanish Society of Rheumatology on risk management of biological treatment and JAK inhibitors in patients with rheumatoid arthritis

    Reumatologia Clinica, Vol. 19, Núm. 10, pp. 533-548

2019

  1. Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept

    PLoS ONE, Vol. 14, Núm. 2

  2. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring in clinical practice: the spanish cohort of the COMORA study

    Reumatologia Clinica, Vol. 15, Núm. 2, pp. 102-108

  3. Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open-Label Trial

    Arthritis and Rheumatology, Vol. 71, Núm. 10, pp. 1616-1625

2018

  1. Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis

    PLoS ONE, Vol. 13, Núm. 5

2017

  1. REDOSER project: optimising biological therapy dose for rheumatoid arthritis and spondyloarthritis patients

    Heliyon, Vol. 3, Núm. 11

2016

  1. Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis

    Pharmacogenomics Journal, Vol. 16, Núm. 2, pp. 137-140

2015

  1. Actualización 2014 del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en la artritis reumatoide

    Reumatologia Clinica, Vol. 11, Núm. 5, pp. 279-294

  2. Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: A case-only study

    Arthritis Research and Therapy, Vol. 17, Núm. 1

2014

  1. Lack of replication of interactions between polymorphisms in rheumatoid arthritis susceptibility: Case-control study

    Arthritis Research and Therapy, Vol. 16, Núm. 1

  2. Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: A genome-wide association study replication and meta-analysis

    Arthritis Research and Therapy, Vol. 16, Núm. 2

2012

  1. The C677T polymorphism in the MTHFR gene is associated with the toxicity of methotrexate in a Spanish rheumatoid arthritis population

    Scandinavian Journal of Rheumatology, Vol. 41, Núm. 1, pp. 10-14

2010

  1. Prediction of functional impairment and remission in rheumatoid arthritis patients by biochemical variables and genetic polymorphisms

    Rheumatology, Vol. 49, Núm. 3, pp. 458-466

2009

  1. Analysis of TNFAIP3, a feedback inhibitor of nuclear factor-κB and the neighbor intergenic 6q23 region in rheumatoid arthritis susceptibility

    Arthritis Research and Therapy, Vol. 11, Núm. 2

  2. Genetic variation in the nuclear factor κB pathway in relation to susceptibility to rheumatoid arthritis

    Annals of the Rheumatic Diseases, Vol. 68, Núm. 4, pp. 579-583

  3. Rheumatoid arthritis does not share most of the newly identified systemic lupus erythematosus genetic factors

    Arthritis and Rheumatism, Vol. 60, Núm. 9, pp. 2558-2564

2005

  1. Association of a functional single-nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with rheumatoid arthritis and systemic lupus erythematosus

    Arthritis and Rheumatism, Vol. 52, Núm. 1, pp. 219-224

2003

  1. A poly(ADP-ribose) polymerase haplotype spanning the promoter region confers susceptibility to rheumatoid arthritis

    Arthritis and Rheumatism, Vol. 48, Núm. 3, pp. 638-641

2002

  1. Genetic determinants of rheumatoid arthritis: The inducible nitric oxide synthase (NOS2) gene promoter polymorphism

    Genes and Immunity, Vol. 3, Núm. 5, pp. 299-301